Revenue
2013
2019
2020
2021
2022
2023
2024
2025
Opus Genetics, Inc. (IRD)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | $589,000 | $0 | $3.0M | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — |
| Research & development | $30.8M | $26.9M | $17.7M | $14.4M | $15.2M | $6.6M | $2.4M | $13.1M | $10.7M | $10.1M | $12.1M | $7.0M | $3.3M | $3.4M | $12.0M | $3.9M | $3.2M | — | — | — | — | — | — | — |
| Operating expenses | $52.8M | $73.1M | $29.6M | $21.6M | $23.3M | $20.0M | $4.2M | $20.5M | $17.4M | $16.4M | $18.3M | $13.3M | $8.0M | $6.6M | $16.1M | $10.3M | $6.5M | — | — | — | — | — | — | — |
| Operating income | −$38.6M | −$62.1M | −$10.6M | $18.2M | −$22.7M | −$20.0M | −$4.2M | −$20.5M | −$17.4M | −$16.4M | −$18.3M | −$13.3M | −$8.0M | −$6.6M | −$16.1M | −$10.3M | −$6.5M | — | — | — | — | — | — | — |
| EBITDAderived | — | — | — | — | — | — | −$4.2M | −$20.5M | −$17.3M | −$16.4M | −$18.2M | −$13.2M | −$7.9M | −$6.5M | −$16.1M | −$10.3M | −$6.4M | — | — | — | — | — | — | — |
| Net income | −$49.6M | −$57.5M | −$10.0M | $17.9M | −$56.7M | −$24.6M | −$6.2M | −$14.4M | −$25.3M | −$9.3M | −$14.4M | −$18.5M | −$9.5M | −$6.2M | −$11.3M | −$14.0M | −$2.9M | −$3.7M | −$4.4M | −$6.5M | −$6.3M | −$3.3M | −$2.8M | −$1.2M |
| Basic EPSper diluted share | -$0.80 | -$2.15 | -$0.46 | $0.90 | -$3.82 | -$5.28 | -$2.17 | -$5.25 | -$0.92 | -$0.43 | -$0.79 | -$0.11 | -$0.07 | -$0.06 | -$0.12 | -$0.18 | -$0.05 | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.80 | -$2.15 | -$0.46 | $0.87 | -$3.82 | -$5.28 | -$2.17 | -$5.25 | -$0.92 | -$0.43 | -$0.79 | -$0.11 | -$0.07 | -$0.06 | -$0.12 | -$0.18 | -$0.05 | — | — | — | — | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4 | Foundation Fighting Blindness Retinal Degeneration Fund +1Director,Other | SellCommon Stock | 1.70M | $4.35 | $7.39M | 3.79M |
| Apr 23, 2026Form 4 | YERXA BENJAMIN RPresident | SellCommon Stock | 7.5K | $5.24 | $39.1K | 711.5K |
| Apr 23, 2026Form 4 | SCHACHLE JOSEPH KChief Operating Officer | SellCommon Stock | 4.7K | $5.22 | $24.5K | 296.1K |
| Apr 23, 2026Form 4 | Zaremba Rabourn AmyHead of Fin. Quality Assurance | SellCommon Stock | 1.6K | $5.20 | $8.5K | 188.7K |
| Apr 23, 2026Form 4 | Magrath GeorgeChief Executive Officer | SellCommon Stock | 9.5K | $5.22 | $49.6K | 1.74M |